Sign Out
REFERO is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥18 years of age (see Pharmacology: Pharmacodynamics under Actions).
In the pivotal study, 91% of the patients were using concomitant lactulose.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Continue with Google